Congenital Hyperinsulinism Center at CHOP

10/31/2025

Happy Halloween!🎃👻Please share pictures of your families Halloween costumes!

10/07/2025

We're thrilled to once again be ranked among the very best in the nation for Endocrinology by U.S. News and World Report!

Children’s Hospital of Philadelphia was again named one of the nation’s best pediatric hospitals by U.S. News & World Report.

09/25/2025

It is National Advanced Practice Providers Week. We want to take this time to recognize and thank our wonderful APP's for their APPceptional work they do for our patients! We are so happy to have Heather, Emily and Molly on our team!!!🌺🌸

09/24/2025

Calling all siblings, friends, and family of the hyperinsulinism community!
We are looking for healthy volunteer participants for a study to understand how cognitive function changes over time in children with hyperinsulinism.
You will be asked to come to CHOP for 3 study visits (one each year) that will each last about 2 hours. At the visit, you will be asked to complete neurocognitive tasks (like computer games) and surveys. Travel support and compensation for your time are provided.
You may be eligible for this study if you are 7 to 15 years old and you have a diagnosis of either congenital hyperinsulinism or are a healthy volunteer. If you’re interested in learning more, please contact us at HIresearch@chop.edu!

07/23/2025

Our team has a new clinical trial for individuals 2 years and older to look at the safety, tolerability, and effectiveness of a new investigational drug called HM15136 which is not yet FDA-approved. HM15136 is a long-acting glucagon analogue given weekly by injection. It is designed to act like glucagon, a hormone produced by the pancreas that helps the body maintain normal blood sugar levels. Total participation time is up to 22 weeks which includes up to 13 study visits and 8 weekly injections of HM15136. Travel and compensation are provided. For more information, please contact us at HIResearch@chop.edu or visit https://www.research.chop.edu/hm15136-for-the-treatment-of-congenital-hyperinsulinism-research-study.

06/07/2025

05/14/2025

Save the date!

05/09/2025

Happy Nurses Week!!

04/09/2025

Our team has a new clinical trial for individuals 1-45 years old to look at the safety, tolerability, and effectiveness of a new investigational drug called RZ358, also known as the sunRIZE study with Rezolute Pharma! RZ358 is being studied as part of this clinical trial and is not yet FDA-approved. It is a specialized protein (called a monoclonal antibody) meant to decrease the effect insulin has on lowering blood sugar and, therefore, improve blood sugar levels in patients with hyperinsulinism. Participation will last for up to 33 weeks or up to 3 years overall if you also join the open-label extension phase of the study. This includes a 5-week Screening Period, a Treatment Period that lasts 24 weeks, an 8-week Follow-up Period, and a 2-year Extension Period where you can continue to receive the study drug if you and the study doctor agree it is beneficial for you. You do not need to participate in the 2-year extension part of the study to take part in the treatment and monitoring period. Travel and compensation are provided! For more information, please contact us at HIResearch@chop.edu.

02/28/2025